https://edgen.beta.edgen.tech/ko/news/post/veracyte-to-present-data-from-2-phase-iii-cancer-trials-at-asco-20262026-05-21T22:25:19.763Zdaily1Edgen Stockko2026-05-21T22:25:19.763+00:00Veracyte, 2026 ASCO 연례 회의에서 2건의 임상 3상 암 시험 데이터 발표 예정https://static.edgen.tech/news/images/veracyte-to-present-data-from-2-phase-iii-cancer-trials-at-asco-2026-20260521.pngVeracyte, 2026 ASCO 연례 회의에서 2건의 임상 3상 암 시험 데이터 발표 예정 https://edgen.beta.edgen.tech/ko/news/post/aktis-aky-2519-shows-404-suvmax-uptake-in-first-human-cancer-trial2026-05-21T22:00:37.556Zdaily1Edgen Stockko2026-05-21T22:00:37.556+00:00Aktis의 AKY-2519, 첫 인체 대상 암 임상시험에서 40.4 SUVmax 섭취 확인https://static.edgen.tech/news/images/aktis-aky-2519-shows-404-suvmax-uptake-in-first-human-cancer-trial-20260521.pngAktis의 AKY-2519, 첫 인체 대상 암 임상시험에서 40.4 SUVmax 섭취 확인 https://edgen.beta.edgen.tech/ko/news/post/zoom-raises-fy2027-forecast-to-over-5-billion-on-ai-demand2026-05-21T21:59:44.545Zdaily1Edgen Stockko2026-05-21T21:59:44.545+00:00Zoom, AI 수요에 힘입어 2027 회계연도 전망치를 50억 달러 이상으로 상향https://static.edgen.tech/news/images/zoom-raises-fy2027-forecast-to-over-5-billion-on-ai-demand-20260521.pngZoom, AI 수요에 힘입어 2027 회계연도 전망치를 50억 달러 이상으로 상향 https://edgen.beta.edgen.tech/ko/news/post/nuvalent-to-show-40-response-rate-for-zidesamtinib-pivotal-lung-cancer-data-at-asco2026-05-21T21:59:21.027Zdaily1Edgen Stockko2026-05-21T21:59:21.027+00:00누발런트, ASCO에서 지데삼티닙 40% 반응률 및 핵심 폐암 데이터 발표 예정https://static.edgen.tech/news/images/nuvalent-to-show-40-response-rate-for-zidesamtinib-pivotal-lung-cancer-data-at-asco-20260521.png누발런트, ASCO에서 지데삼티닙 40% 반응률 및 핵심 폐암 데이터 발표 예정 https://edgen.beta.edgen.tech/ko/news/post/amex-exploration-secures-c59-million-to-fund-perron-gold-project2026-05-21T21:56:33.508Zdaily1Edgen Stockko2026-05-21T21:56:33.508+00:00Amex Exploration, 페론 금 프로젝트 자금 조달을 위해 5,900만 캐나다 달러 확보https://static.edgen.tech/news/images/amex-exploration-secures-c59-million-to-fund-perron-gold-project-20260521.pngAmex Exploration, 페론 금 프로젝트 자금 조달을 위해 5,900만 캐나다 달러 확보 https://edgen.beta.edgen.tech/ko/news/post/turkish-stocks-plunge-6-after-court-ousts-opposition-leader2026-05-21T21:38:28.380Zdaily1Edgen Stockko2026-05-21T21:38:28.380+00:00법원의 야당 대표 해임 결정에 터키 증시 6% 급락https://static.edgen.tech/news/images/turkish-stocks-plunge-6-after-court-ousts-opposition-leader-20260521.png법원의 야당 대표 해임 결정에 터키 증시 6% 급락 https://edgen.beta.edgen.tech/ko/news/post/black-diamond-rises-on-152-month-cancer-trial-result2026-05-21T21:33:26.576Zdaily1Edgen Stockko2026-05-21T21:33:26.576+00:00블랙 다이아몬드, 15.2개월 암 임상 결과 발표로 주가 급등https://static.edgen.tech/news/images/black-diamond-rises-on-152-month-cancer-trial-result-20260521.png블랙 다이아몬드, 15.2개월 암 임상 결과 발표로 주가 급등 https://edgen.beta.edgen.tech/ko/news/post/why-a-9010-portfolio-may-be-better-than-6040-for-some-investors2026-05-21T21:32:58.406Zdaily1Edgen Stockko2026-05-21T21:32:58.406+00:00왜 일부 투자자에게는 90/10 포트폴리오가 60/40보다 나을 수 있는가https://static.edgen.tech/news/images/why-a-9010-portfolio-may-be-better-than-6040-for-some-investors-20260521.png왜 일부 투자자에게는 90/10 포트폴리오가 60/40보다 나을 수 있는가 https://edgen.beta.edgen.tech/ko/news/post/merck-lung-cancer-combo-with-kelun-hits-70-response-rate2026-05-21T21:32:56.338Zdaily1Edgen Stockko2026-05-21T21:32:56.338+00:00머크-켈룬 바이오텍 폐암 병용 요법, 반응률 70% 달성https://static.edgen.tech/news/images/merck-lung-cancer-combo-with-kelun-hits-70-response-rate-20260521.png머크-켈룬 바이오텍 폐암 병용 요법, 반응률 70% 달성 https://edgen.beta.edgen.tech/ko/news/post/imax-surges-15-on-reports-of-a-potential-sale2026-05-21T21:30:24.927Zdaily1Edgen Stockko2026-05-21T21:30:24.927+00:00IMAX, 매각 검토 소식에 주가 15% 급등https://static.edgen.tech/news/images/imax-surges-15-on-reports-of-a-potential-sale-20260521.pngIMAX, 매각 검토 소식에 주가 15% 급등 https://edgen.beta.edgen.tech/ko/news/post/bicara-cancer-drug-doubles-survival-rate-to-31-in-head-and-neck-trial2026-05-21T21:29:39.317Zdaily1Edgen Stockko2026-05-21T21:29:39.317+00:00Bicara 암 치료제, 두경부암 임상에서 생존율 31%로 두 배 향상https://static.edgen.tech/news/images/bicara-cancer-drug-doubles-survival-rate-to-31-in-head-and-neck-trial-20260521.pngBicara 암 치료제, 두경부암 임상에서 생존율 31%로 두 배 향상 https://edgen.beta.edgen.tech/ko/news/post/syndax-to-present-new-revuforj-data-from-4-leukemia-trials-at-asco2026-05-21T21:28:58.937Zdaily1Edgen Stockko2026-05-21T21:28:58.937+00:00신닥스, ASCO에서 4건의 백혈병 임상시험을 통한 레부포르즈 데이터 발표 예정https://static.edgen.tech/news/images/syndax-to-present-new-revuforj-data-from-4-leukemia-trials-at-asco-20260521.png신닥스, ASCO에서 4건의 백혈병 임상시험을 통한 레부포르즈 데이터 발표 예정 https://edgen.beta.edgen.tech/ko/news/post/remix-drug-shows-43-response-rate-in-rare-cancer-trial2026-05-21T21:26:22.698Zdaily1Edgen Stockko2026-05-21T21:26:22.698+00:00리믹스 테라퓨틱스, 희귀암 임상서 43% 반응률 기록https://static.edgen.tech/news/images/remix-drug-shows-43-response-rate-in-rare-cancer-trial-20260521.png리믹스 테라퓨틱스, 희귀암 임상서 43% 반응률 기록 https://edgen.beta.edgen.tech/ko/news/post/akaris-cancer-drug-shows-high-synergy-with-kras-inhibitors2026-05-21T21:26:17.317Zdaily1Edgen Stockko2026-05-21T21:26:17.317+00:00Akari 암 치료제, KRAS 억제제와 높은 시너지 효과 확인https://static.edgen.tech/news/images/akaris-cancer-drug-shows-high-synergy-with-kras-inhibitors-20260521.pngAkari 암 치료제, KRAS 억제제와 높은 시너지 효과 확인 https://edgen.beta.edgen.tech/ko/news/post/dow-surges-351-points-to-new-record-as-investors-rotate-to-tech2026-05-21T21:25:29.573Zdaily1Edgen Stockko2026-05-21T21:25:29.573+00:00다우 지수, 기술주 순환매 속 351포인트 상승하며 사상 최고치 경신https://static.edgen.tech/news/images/dow-surges-351-points-to-new-record-as-investors-rotate-to-tech-20260521.png다우 지수, 기술주 순환매 속 351포인트 상승하며 사상 최고치 경신 https://edgen.beta.edgen.tech/ko/news/post/seer-rejects-radoff-jecs-240-per-share-takeover-bid2026-05-21T20:56:36.493Zdaily1Edgen Stockko2026-05-21T20:56:36.493+00:00시어(Seer), 라도프-JEC의 주당 2.40달러 인수 제안 거절https://static.edgen.tech/news/images/seer-rejects-radoff-jecs-240-per-share-takeover-bid-20260521.png시어(Seer), 라도프-JEC의 주당 2.40달러 인수 제안 거절 https://edgen.beta.edgen.tech/ko/news/post/lucid-group-faces-fraud-inquiry-after-revenue-miss-sinks-stock-72026-05-21T20:55:35.719Zdaily1Edgen Stockko2026-05-21T20:55:35.719+00:00루시드 그룹, 매출 미달로 주가 7% 폭락 후 사기 조사 직面https://static.edgen.tech/news/images/lucid-group-faces-fraud-inquiry-after-revenue-miss-sinks-stock-7-20260521.png루시드 그룹, 매출 미달로 주가 7% 폭락 후 사기 조사 직面 https://edgen.beta.edgen.tech/ko/news/post/baycom-stock-drops-11-as-law-firm-probes-executive-exodus2026-05-21T20:55:26.128Zdaily1Edgen Stockko2026-05-21T20:55:26.128+00:00BayCom, 경영진 대거 사퇴에 따른 법무법인 조사로 주가 11% 하락https://static.edgen.tech/news/images/baycom-stock-drops-11-as-law-firm-probes-executive-exodus-20260521.pngBayCom, 경영진 대거 사퇴에 따른 법무법인 조사로 주가 11% 하락 https://edgen.beta.edgen.tech/ko/news/post/carmax-faces-investor-investigation-after-stock-plunges-152026-05-21T20:55:23.361Zdaily1Edgen Stockko2026-05-21T20:55:23.361+00:00카맥스(CarMax), 주가 15% 폭락 후 투자자 조사 직면https://static.edgen.tech/news/images/carmax-faces-investor-investigation-after-stock-plunges-15-20260521.png카맥스(CarMax), 주가 15% 폭락 후 투자자 조사 직면 https://edgen.beta.edgen.tech/ko/news/post/abbvies-boey-gets-positive-eu-opinion-for-30-markets2026-05-21T20:31:25.919Zdaily1Edgen Stockko2026-05-21T20:31:25.919+00:00애브비의 Boey, 유럽 30개 시장서 긍정적 의견 획득https://static.edgen.tech/news/images/abbvies-boey-gets-positive-eu-opinion-for-30-markets-20260521.png애브비의 Boey, 유럽 30개 시장서 긍정적 의견 획득